发布求助
文献互助 智能选刊 最新文献

Cancer Investigation最新文献

筛选
英文 中文
Perception, Cognition and Thought: Part IV Consciousness, Awareness, and "I". 知觉、认知和思想:第四部分意识、觉知和“我”。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-10-01 Epub Date: 2023-08-23 DOI: 10.1080/07357907.2023.2248785
Gary H Lyman, Christopher H Lyman, Nicole M Kuderer
{"title":"Perception, Cognition and Thought: Part IV Consciousness, Awareness, and \"I\".","authors":"Gary H Lyman, Christopher H Lyman, Nicole M Kuderer","doi":"10.1080/07357907.2023.2248785","DOIUrl":"10.1080/07357907.2023.2248785","url":null,"abstract":"Either mathematics is too big for the human mind, or the human mind is more than a machine. -","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"751-756"},"PeriodicalIF":2.4,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10037147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
In Vitro and In Vivo Synergistic Antitumor Activity of Albumin-Coated Oleic Acid-Loaded Liposomes toward Hepatocellular Carcinoma. 白蛋白包被油酸脂质体对肝癌的体内外协同抗肿瘤活性研究。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2241083
Esmail M El-Fakharany, Mahmoud Ashry, Marwa M Abu-Serie, Khaled G Abdel-Wahhab, Doaa Galal El-Sahra, Hamada El-Gendi
{"title":"<i>In Vitro and In Vivo</i> Synergistic Antitumor Activity of Albumin-Coated Oleic Acid-Loaded Liposomes toward Hepatocellular Carcinoma.","authors":"Esmail M El-Fakharany,&nbsp;Mahmoud Ashry,&nbsp;Marwa M Abu-Serie,&nbsp;Khaled G Abdel-Wahhab,&nbsp;Doaa Galal El-Sahra,&nbsp;Hamada El-Gendi","doi":"10.1080/07357907.2023.2241083","DOIUrl":"https://doi.org/10.1080/07357907.2023.2241083","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the most lethal and prevalent cancers, closely associated with cirrhosis and fibrosis. This study aimed to assess the antitumor activity of oleic acid-liposomes (uncoated liposomes) upon coating with albumin against HCC. The <i>in vitro</i> studies revealed the high safety of the prepared uncoated and albumin-coated liposomes to normal HFB-4 cells (EC<sub>100</sub> of 35.57 ± 0.17 and 79.133 ± 2.92 µM, respectively) with significant anticancer activity against HepG-2 cells with IC<sub>50</sub> of 56.29 ± 0.91 and 26.74 ± 0.64 µM, respectively. The albumin-coated liposomes revealed superior apoptosis induction potential (80.7%) with significant upregulation of p53 gene expression (<math><mo>></mo></math>7.0-fold), compared to OA. The <i>in vivo</i> study revealed that the administration of uncoated or albumin-coated liposomes (100 mg/kg) for six weeks markedly retarded the DENA-induced HCC in Wistar albino rates through regulating the liver enzymes, total bilirubin level, pro-inflammatory cytokines, and oxidative stress. Accordingly, the current study supports the <i>in vitro</i> and <i>in vivo</i> chemo-preventive feature of albumin-coated liposomes against HCC through modulation of apoptosis, improvement of the immune response, reduction of inflammation, and restoration of impaired oxidative stress, which is the first reported to the best of our knowledge.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"621-639"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10223087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma. 肿瘤分化作为临床分期T1bN0食管腺癌的预后标志物。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-09-04 DOI: 10.1080/07357907.2023.2255907
Ofer Margalit, Einat Shacham-Shmueli, Gal Strauss, Yu-Xiao Yang, Yaacov R Lawerence, Alon Ben Nun, Idan Levy, Kim A Reiss, Talia Golan, Naama Halpern, Dan Aderka, Bruce Giantonio, Ronac Mamtani, Ben Boursi
{"title":"Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma.","authors":"Ofer Margalit,&nbsp;Einat Shacham-Shmueli,&nbsp;Gal Strauss,&nbsp;Yu-Xiao Yang,&nbsp;Yaacov R Lawerence,&nbsp;Alon Ben Nun,&nbsp;Idan Levy,&nbsp;Kim A Reiss,&nbsp;Talia Golan,&nbsp;Naama Halpern,&nbsp;Dan Aderka,&nbsp;Bruce Giantonio,&nbsp;Ronac Mamtani,&nbsp;Ben Boursi","doi":"10.1080/07357907.2023.2255907","DOIUrl":"10.1080/07357907.2023.2255907","url":null,"abstract":"<p><p>Current guidelines recommend that clinically staged T1N0 esophageal cancers are to be referred to surgery or endoscopic resection. Using the National Cancer Database, we identified 733 individuals with clinically staged T1N0 esophageal carcinoma, who underwent upfront surgery and did not receive any prior treatment. We assessed upstaging, which was defined as ≥ T2 disease or positive lymph nodes. Poorly differentiated adenocarcinomas were associated with upstaging, whereas squamous cell carcinomas were not. Specifically, the percentage of upstaging among individuals with clinically staged T1b and poorly differentiated tumor was 33.8%. Therefore, clinically staged T1bN0 poorly differentiated esophageal adenocarcinomas are at high risk for upstaging following surgery.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"734-738"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telomere Shortening of Barrett's Esophagus and Esophageal Adenocarcinoma in Japanese Patients. 日本巴雷特食管和食管腺癌患者端粒缩短。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2245897
Tomomitsu Tahara, Takuya Shijimaya, Jumpei Yamazaki, Takashi Tomiyama, Toshiro Fukui, Makoto Naganuma
{"title":"Telomere Shortening of Barrett's Esophagus and Esophageal Adenocarcinoma in Japanese Patients.","authors":"Tomomitsu Tahara,&nbsp;Takuya Shijimaya,&nbsp;Jumpei Yamazaki,&nbsp;Takashi Tomiyama,&nbsp;Toshiro Fukui,&nbsp;Makoto Naganuma","doi":"10.1080/07357907.2023.2245897","DOIUrl":"https://doi.org/10.1080/07357907.2023.2245897","url":null,"abstract":"<p><p>Telomere shortening is deeply involved in many types of cancer. Telomere length of esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE) was examined in Japanese patients. Among BE from cancer free patients (Cancer free), BE from patients with EAC (Adjacent) and EAC tissue (Cancer), Cancer free group presented the longest telomeres, while Cancer group presented the shortest telomeres and Adjacent group presented intermediate telomeres. Direction of endoscopic biopsy, 2 o'clock direction was also significantly associated with shorter telomere length in non-neoplastic BE (<i>p</i> = 0.027). Shortened telomere highlighted the impact of this molecular change in early carcinogenesis in EAC.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"640-645"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10168095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunohistochemical Analysis of Lung Adenocarcinoma in Russian Mayak Nuclear Workers. 俄罗斯Mayak核工人肺腺癌的免疫组化分析。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2218489
Gleb V Sychugov, Tamara V Azizova, Galina V Zhuntova, Evgeniya S Grigoryeva, Christopher A Loffredo, Nobuyuki Hamada, Evgeniy L Kazachkov
{"title":"Immunohistochemical Analysis of Lung Adenocarcinoma in Russian Mayak Nuclear Workers.","authors":"Gleb V Sychugov,&nbsp;Tamara V Azizova,&nbsp;Galina V Zhuntova,&nbsp;Evgeniya S Grigoryeva,&nbsp;Christopher A Loffredo,&nbsp;Nobuyuki Hamada,&nbsp;Evgeniy L Kazachkov","doi":"10.1080/07357907.2023.2218489","DOIUrl":"https://doi.org/10.1080/07357907.2023.2218489","url":null,"abstract":"<p><p>Specimens of lung adenocarcinoma (AdCa) from Russian nuclear workers (<i>n</i> = 54) exposed to alpha particles and gamma rays and from individuals non-exposed to radiation (<i>n</i> = 21) were examined using immunohistochemistry. Estimated significant associations with alpha dose were negative for Ki-67 and collagen IV in AdCa. Associations with gamma-ray dose were negative for tissue inhibitor of matrix metalloproteinase 2 and caspase 3 and positive for matrix metalloproteinase 2 and leukemia inhibiting factor in AdCa. The findings provide some evidence supporting alterations in apoptosis, cell proliferation and extracellular matrix in lung tissues affected by chronic radiation exposure that can contribute to radiogenic cancerogenesis.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"686-698"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10166550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug Repurposing Analysis for Colorectal Cancer through Network Medicine Framework: Novel Candidate Drugs and Small Molecules. 通过网络医学框架对癌症大肠癌的药物再利用分析：新的候选药物和小分子。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-09-08 DOI: 10.1080/07357907.2023.2255672
Ulku Unal, Esra Gov
{"title":"Drug Repurposing Analysis for Colorectal Cancer through Network Medicine Framework: Novel Candidate Drugs and Small Molecules.","authors":"Ulku Unal,&nbsp;Esra Gov","doi":"10.1080/07357907.2023.2255672","DOIUrl":"10.1080/07357907.2023.2255672","url":null,"abstract":"<p><p>This study aimed to reveal the drug-repurposing candidates for colorectal cancer (CRC) <i>via</i> drug-repurposing methods and network biology approaches. A novel, differentially co-expressed, highly interconnected, and co-regulated prognostic gene module was identified for CRC. Based on the gene module, polyethylene glycol (PEG), gallic acid, pyrazole, cordycepin, phenothiazine, pantoprazole, cysteamine, indisulam, valinomycin, trametinib, BRD-K81473043, AZD8055, dovitinib, BRD-A17065207, and tyrphostin AG1478 presented as drugs and small molecule candidates previously studied in the CRC. Lornoxicam, suxamethonium, oprelvekin, sirukumab, levetiracetam, sulpiride, NVP-TAE684, AS605240, 480743.cdx, HDAC6 inhibitor ISOX, BRD-K03829970, and L-6307 are proposed as novel drugs and small molecule candidates for CRC.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"713-733"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10173920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraosseous Spindle Cell Rhabdomyosarcoma with MEIS1::NCOA2 Fusion - Case Report with Substantial Clinical Follow-up and Review of the Literature. 伴有MEIS1:：NCOA2融合的骨内梭形细胞横纹肌肉瘤——病例报告及大量临床随访和文献复习。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-09-06 DOI: 10.1080/07357907.2023.2255668
Benjamin F Smith, Yee-Cheen Doung, Brooke Beckett, Christopher L Corless, Lara E Davis, Jessica L Davis
{"title":"Intraosseous Spindle Cell Rhabdomyosarcoma with <i>MEIS1</i>::<i>NCOA2</i> Fusion - Case Report with Substantial Clinical Follow-up and Review of the Literature.","authors":"Benjamin F Smith,&nbsp;Yee-Cheen Doung,&nbsp;Brooke Beckett,&nbsp;Christopher L Corless,&nbsp;Lara E Davis,&nbsp;Jessica L Davis","doi":"10.1080/07357907.2023.2255668","DOIUrl":"10.1080/07357907.2023.2255668","url":null,"abstract":"<p><p>Spindle cell/sclerosing rhabdomyosarcoma (SSRMS) is a clinicopathologically and molecularly heterogeneous disease. Gene fusions have been identified in intraosseous SSRMS, consisting predominantly of <i>EWSR1</i>/<i>FUS</i>::<i>TFCP2</i> and <i>MEIS1</i>::<i>NCOA2</i>. The former often follow an aggressive clinical course; there is limited clinical follow-up available for the latter. We report here a new case of the very rare intraosseous SSRMS with <i>MEIS1</i>::<i>NCOA2</i> gene fusion and include the detailed treatment course and 52 months of clinical follow-up. SSRMS with <i>MEIS1</i>::<i>NCOA2</i> gene fusion appears biologically distinct from other intraosseous SSRMS, following a course characterized by local recurrence with rare reports of metastasis to date.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"704-712"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10158690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review. RET特异性激酶抑制剂在RET改变的癌症中的疗效和安全性：一项系统综述。
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-10-31 DOI: 10.1080/07357907.2023.2255655
Muhammad Ashar Ali, Syed S Shah, Rimsha Ali, Shammas Farooq Bajwa, Sana Rehman, Aqsa Anwar, Muhammad Yasir Anwar, Memoona Saeed, Nayab Mirza, Wajeeha Aiman
{"title":"Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers: A Systematic Review.","authors":"Muhammad Ashar Ali,&nbsp;Syed S Shah,&nbsp;Rimsha Ali,&nbsp;Shammas Farooq Bajwa,&nbsp;Sana Rehman,&nbsp;Aqsa Anwar,&nbsp;Muhammad Yasir Anwar,&nbsp;Memoona Saeed,&nbsp;Nayab Mirza,&nbsp;Wajeeha Aiman","doi":"10.1080/07357907.2023.2255655","DOIUrl":"10.1080/07357907.2023.2255655","url":null,"abstract":"<p><p>RET proto-oncogene encodes receptor tyrosine kinase. Selpercatinib and pralsetinib are the only RET-specific tyrosine kinase inhibitors approved by FDA in RET-altered tumors. We searched PubMed, Embase, Cochrane, WOS, and Clinicaltrials.gov. Objective-response, complete-response, and partial-response were 60-89%, 0-11%, and 55-89%, respectively, with the use of RET-specific drugs. ≥Grade 3 adverse events were seen in 28-53% of the patients, with hypertension, change in ALT, QT prolongation, neutropenia, and pneumonitis among the common side effects. Hence, selpercatinib and pralsetinib were effective and well tolerated by most of the patients with RET-altered tumors.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"739-749"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41107922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 校正
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 Epub Date: 2023-10-31 DOI: 10.1080/07357907.2023.2259655
{"title":"Correction.","authors":"","doi":"10.1080/07357907.2023.2259655","DOIUrl":"10.1080/07357907.2023.2259655","url":null,"abstract":"","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"750"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41124931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Cancer-Associated Fibroblasts on Drug Resistance, Stemness, and Epithelial-Mesenchymal Transition in Bladder Cancer: A Comparison between Recurrent and Non-Recurrent Patient-Derived CAFs. 癌症相关成纤维细胞对膀胱癌耐药、干细胞和上皮-间质转化的影响:复发性和非复发性患者源性CAFs的比较
IF 2.4 4区 医学
Cancer Investigation Pub Date : 2023-09-01 DOI: 10.1080/07357907.2023.2237576
Nima Rastegar-Pouyani, Vahideh Montazeri, Nikoo Marandi, Shima Aliebrahimi, Melika Andalib, Emad Jafarzadeh, Hamed Montazeri, Seyed Nasser Ostad
{"title":"The Impact of Cancer-Associated Fibroblasts on Drug Resistance, Stemness, and Epithelial-Mesenchymal Transition in Bladder Cancer: A Comparison between Recurrent and Non-Recurrent Patient-Derived CAFs.","authors":"Nima Rastegar-Pouyani,&nbsp;Vahideh Montazeri,&nbsp;Nikoo Marandi,&nbsp;Shima Aliebrahimi,&nbsp;Melika Andalib,&nbsp;Emad Jafarzadeh,&nbsp;Hamed Montazeri,&nbsp;Seyed Nasser Ostad","doi":"10.1080/07357907.2023.2237576","DOIUrl":"https://doi.org/10.1080/07357907.2023.2237576","url":null,"abstract":"<p><p>This study comparatively evaluated the possible effects of recurrent and non-recurrent patient-derived Cancer-Associated Fibroblasts (CAFs-R and -NR) on the bladder cancer cell line, EJ138. Both groups of CAFs increased cisplatin resistance and altered cell cycle distribution alongside induced resistance to apoptosis. Later, the scratch assay confirmed the cell migration-inducing effects of CAFs on cells. Nonetheless, only CAFs-R managed to increase sphere-formation and clonogenic levels in EJ138 cells, which were later validated by upregulating pluripotency transcription factors. Besides, CAFs-R also affected the expression levels of some of the EMT markers. Our study suggests that CAFs-R had stronger pro-tumorigenic effects on EJ138 cells.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"41 7","pages":"656-671"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10157610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信